|Bid||1.4700 x 100|
|Ask||1.4800 x 100|
|Day's Range||1.3500 - 1.5000|
|52 Week Range||1.3500 - 8.2000|
|PE Ratio (TTM)||-0.43|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Q2 2017 TearLab Corp Earnings Call
The San Diego-based company said it had a loss of 68 cents per share. The ophthalmic device company posted revenue of $7 million in the period, which topped Street forecasts. Three analysts surveyed by ...
Cytori Therapeutics Inc: Should You Catch This Falling Knife? Cytori Therapeutics Inc (NASDAQ:CYTX) shares are crashing over 60% in Monday's trading session, after the biotech company disclosed that its pivotal STAR study assessing Habeo Cell Therapy for the treatment of scleroderma failed to achieve its primary endpoint at week 24 nor any of its secondary endpoints at week 24 or week 48. Kolbert noted, "The totality of the data combined with the investigator comments matter and suggest to us that there maybe a window for approval based on the current data set and/or a small bridging study.